Vaccine evaluation: lessons from a meningococcal B vaccine.

Arch Dis Child

Paediatric Intensive Care, Paediatric Intensive Care Unit, St. Mary's Hospital and Imperial College London, London, UK.

Published: June 2015

Download full-text PDF

Source
http://dx.doi.org/10.1136/archdischild-2014-306030DOI Listing

Publication Analysis

Top Keywords

vaccine evaluation
4
evaluation lessons
4
lessons meningococcal
4
meningococcal vaccine
4
vaccine
2
lessons
1
meningococcal
1

Similar Publications

Background: Cerebral venous sinus thrombosis (CVST) is a rare yet significant neurological disorder with high mortality. Understanding its evolving characteristics, risk factors, and outcomes, particularly in Chinese patients after the COVID-19 pandemic, is critical for developing effective preventive and therapeutic strategies.

Methods: A retrospective analysis was conducted on 471 CVST cases from Xuanwu Hospital, comparing data before (2013-2017, n = 243) and after (2021-2023, n = 228) the COVID-19 pandemic.

View Article and Find Full Text PDF

Helicobacter pylori (H. pylori) is an extremely prevalent human pathogen globally that leads to severe illnesses. Sadly, the worldwide issue of H.

View Article and Find Full Text PDF

Background: In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1-9 years in Niger.

Methods: In this three-arm, open-label, cluster-randomised trial, 63 clusters of one to four villages in Niger were randomly assigned (3:3:1) using block randomisation to receive campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign.

View Article and Find Full Text PDF

Long-term evaluation in BALBc mice of a triple mutant of Mycobacterium bovis and the Bacillus Calmette-Guérin as potential vaccines against bovine tuberculosis.

Vet Microbiol

January 2025

Instituto de Agrobiotecnología y Biología Molecular, (IABIMO) INTA-CONICET, Argentina; Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, N. Repetto and De los Reseros, Hurlingham, Buenos Aires 1686, Argentina. Electronic address:

There is currently no commercial vaccine available against bovine tuberculosis (bTB). Mycobacterium bovis is the primary causative agent of bTB and is closely related to Mycobacterium tuberculosis, the pathogen responsible for human TB. Despite their limitations, mouse models are invaluable in early vaccine development due to their genetic diversity, cost-effectiveness, and the availability of research tools.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess how different routes of vaccine administration and the use of injectable trace minerals (ITM) affect immune responses in dairy calves infected with BVDV2 and BHV1.
  • A total of 60 calves were vaccinated and monitored for immune cell counts, revealing that unvaccinated calves showed significantly lower leukocyte levels compared to vaccinated ones.
  • Results indicated that calves receiving subcutaneous vaccinations had better immune response, particularly in CD4 T cells, and those in the ITM-IN group had the highest CD8 T cell counts, highlighting the importance of both the vaccination method and ITM usage in immune system effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!